Antidiabetic Nateglinide Purity Nateglinide Raw Powder Nateglinide

Model NO.
D-sung Nateglinide
Shelf Life
2 Years
CAS No.
105816-04-4
Test Method
HPLC
Specific
COA
Density
1.104
Melting Point
137-141ºC
MW
317.42258
Mf
C19h27no3
Grade
Pharmaceutical Grade
Color
White
Application
Antidiabetic
Assay
HPLC 99%
Name
Nateglinide Powder
Appearance
White Powder
Product Name
Nateglinide
Transport Package
Negotiable
Specification
99%
Trademark
D-sung
Origin
Shaanxi Xi′an
Production Capacity
500kg/Month
Reference Price
$ 180.00 - 252.00
Contact Us

Product Description

Antidiabetic Nateglinide Purity Nateglinide Raw Powder Nateglinide
Antidiabetic Nateglinide Purity Nateglinide Raw Powder Nateglinide
Product Description
Antidiabetic Nateglinide Purity Nateglinide Raw Powder Nateglinide Antidiabetic Nateglinide Purity Nateglinide Raw Powder Nateglinide
Product Details
Antidiabetic Nateglinide Purity Nateglinide Raw Powder Nateglinide
Product name Nateglinide
Appearance White powder
CAS NO. 105816-04-4
MF C19H27NO3
MW 317.42258
Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insuli-Diabetes drug API Nateglinide/trans-d-phenylalanine CAS 105816-04-4dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insuli secretagogues, which act by binding to β cells of the pancreas to stimulate insuli release. Nateglinide is an amino acid derivative that induces an early insuli response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insuli and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Nateglinide is extensively metabolized in the liver and excreted in urine (83%) and feces (10%). The major metabolites possess less activity than the parent compound. One minor metabolite, the isoprene, has the same potency as its parent compound.
Application&Function
Antidiabetic Nateglinide Purity Nateglinide Raw Powder Nateglinide 1. Nateglinide is used for the treatment of the form of diabetes mellitus that appears most frequently in adulthood -- known as type 2 or non-insuli-dependent diabetes -- that cannot be managed by exercise and control of diet alone.

2. Nateglinide may be added to diet and exercise to manage the disease, or it may be combined with metformin when diet, exercise, and either drug alone cannot provide adequate control of blood sugar.
Specification
Antidiabetic Nateglinide Purity Nateglinide Raw Powder Nateglinide Antidiabetic Nateglinide Purity Nateglinide Raw Powder Nateglinide Antidiabetic Nateglinide Purity Nateglinide Raw Powder Nateglinide
Antidiabetic Nateglinide Purity Nateglinide Raw Powder Nateglinide Antidiabetic Nateglinide Purity Nateglinide Raw Powder Nateglinide Antidiabetic Nateglinide Purity Nateglinide Raw Powder Nateglinide

 

 

Pharmaceutical Intermediate

GOUV.NE, 2023